Core Insights - The company has exceeded its cash and profitability targets for FY 2025, achieving a revenue target of over €8 billion, specifically estimated at €8,001 million [4][6] - The book-to-bill ratio for Q4 2025 was 122%, indicating a positive commercial momentum and alignment with expectations for year-end order entry levels [6][7] Revenue Performance - Group revenue for Q4 2025 is estimated at €2,004 million, reflecting a -9.3% organic decline compared to Q4 2024, primarily due to contract losses and a weak market environment [2][6] - The Atos Strategic Business Unit (SBU) generated estimated revenue of €1,738 million in Q4 2025, down -9% organically compared to Q4 2024, while the Eviden SBU's revenue decreased by -11.2% to €265 million [3][6] Full-Year Financials - For FY 2025, the Atos SBU's revenue is estimated at €6,963 million, a -16.2% organic decline compared to FY 2024, whereas the Eviden SBU's revenue is estimated to have increased by +6.7% to €1,039 million [4][6] - The estimated net change in cash for FY 2025 is limited to approximately €-327 million, which is above the target, and the company maintained a strong liquidity position of €1,707 million at year-end [6][10] Commercial Activity - Order entry reached €2,444 million in Q4 2025, with notable acceleration in North America, Germany, and Benelux, benefiting from a customer relationship agreement with Siemens AG [7][6] - The Atos SBU's book-to-bill ratio was 106%, while the Eviden SBU achieved a book-to-bill ratio of 229%, significantly up from the previous year due to a major contract [13][6] Outlook - The company expects to exceed its profitability target for FY 2025 with an operating margin above €340 million, representing over 4% of revenues [11] - Financial targets for FY 2026 will be communicated on March 6, 2026, alongside the release of audited financial statements for FY 2025 [11]
FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan